Helix BioPharma Corp. Initiates Enrollment for Fourteenth Cohort in Polish Phase I/II Clinical Study of Its L-DOS47 Lung Cancer Drug

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of cancer, today announced the
opening of patient screening for the fourteenth dose level cohort in the Company’s ongoing Phase I/II
clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”).